近日，信达生物交出2025年成绩单：全年营收约119亿元，同比增长45%。更关键的信号是公司预计净利润同步攀升，这标志着其已跨越“投入期”，步入扎实的“收获期”。拆解信达的增长轨迹，韧性尤为明显，在首次跨入“百亿营收俱乐部”的这一年，信达生物季度业绩持续走强。特别是去年Q4，信达为即将在2026年执行新医保价格的6款新药，对渠道库存进行了“补差处理”。即便扣除这笔开支，单季收入依旧实现超60%同比...
Source Link近日，信达生物交出2025年成绩单：全年营收约119亿元，同比增长45%。更关键的信号是公司预计净利润同步攀升，这标志着其已跨越“投入期”，步入扎实的“收获期”。拆解信达的增长轨迹，韧性尤为明显，在首次跨入“百亿营收俱乐部”的这一年，信达生物季度业绩持续走强。特别是去年Q4，信达为即将在2026年执行新医保价格的6款新药，对渠道库存进行了“补差处理”。即便扣除这笔开支，单季收入依旧实现超60%同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.